Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)

Inclusion Criteria: 1. Sign written informed consent before implementing any experimental procedures; 2. Age range: 18-80 years old; 3. Pathological diagnosis of small cell lung cancer; 4. Limited stage; 5. ECOG PS 0-1； 6. Receive ≤ 2 rounds of chemotherapy or chemotherapy plus immunotherapy; 7. Expected survival time\>3 months; Exclusion Criteria: 1. Progress after 2 induction treatments; 2. Severe emphysema, interstitial changes in the lungs, COPD patients; 3. Resting blood oxygen\<93; 4. Have a history of other malignant tumors and have received chemotherapy in the past 3 years; 5. History of chest radiotherapy;